Craig-Hallum Starts Design Therapeutics Inc (DSGN) at Buy

Craig-Hallum analyst Adam Vogel initiates coverage on Design Therapeutics Inc (NASDAQ: DSGN) with a Buy rating and a price target of $15.00.

The analyst comments "Thoughts on shares. Shares are up 45% YTD vs. XBI’s 32%, currently implying an EV of ~ $300MM. We see DSGN as an underappreciated GeneTAC platform name where upcoming FA and Fuchs readouts inn 2H26 can catalyze a transition from a show-me skepticism to a de-risked, multi-asset genetic-medicine story not reflected in current valuation."

For an analyst ratings summary and ratings history on Design Therapeutics Inc click here. For more ratings news on Design Therapeutics Inc click here.

Shares of Design Therapeutics Inc closed at $8.94 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• JPMorgan Downgrades Indorama Ventures PCL (IVL:TB) to Neutral
• Kepler Cheuvreux Downgrades Carl Zeiss Meditec AG (AFXG:GR) (CZMWY) to Reduce